|
|
|
|
Дата |
|---|
| 18:52 |
| 24.07.2026 |
| 23.07.2026 |
| 22.07.2026 |
| 21.07.2026 |
| 20.07.2026 |
| 17.07.2026 |
| 16.07.2026 |
| 15.07.2026 |
| 14.07.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
12.26
|
12.45
|
12.84
|
11.41
|
14.39
|
12.40
|
|
|
6 121 678.08
|
5 216.00
|
|
32.12
|
40.29
|
35.68
|
34.60
|
36.90
|
36.61
|
|
|
1 764 806.85
|
605.00
|
|
31.84
|
40.29
|
34.61
|
34.60
|
36.01
|
35.20
|
|
|
1 705 217.89
|
482.00
|
|
31.82
|
40.30
|
37.68
|
35.28
|
37.68
|
35.28
|
|
|
1 092 848.16
|
484.00
|
|
19.02
|
40.29
|
37.38
|
36.55
|
38.09
|
37.37
|
|
|
1 246 833.10
|
792.00
|
|
33.39
|
40.00
|
38.16
|
35.98
|
38.16
|
35.98
|
|
|
2 933 738.55
|
908.00
|
|
18.72
|
40.00
|
36.50
|
36.245
|
38.39
|
37.825
|
|
|
5 017 813.56
|
1 334.00
|
|
18.72
|
40.00
|
37.25
|
36.10
|
38.00
|
37.22
|
|
|
2 146 859.21
|
687.00
|
|
18.71
|
40.31
|
37.12
|
35.68
|
37.32
|
37.30
|
|
|
3 040 146.04
|
878.00
|
|
18.72
|
40.00
|
36.83
|
36.15
|
38.16
|
37.81
|
|
|
1 346 855.55
|
487.00
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded by leading experts in psychiatry and neuroscience, dedicated to addressing significant unmet medical needs in central nervous system (CNS) disorders. The firm’s proprietary discovery platform-leveraging optogenetics, spatial transcriptomics (STARmap) and circuit-based neuroscience-aims to identify and modulate the specific neural circuits underlying diseases. Their lead candidate, ML-007C-MA (an M/M muscarinic agonist co-formulated with a peripherally acting anticholinergic), is currently in Phase 2 development for indications including schizophrenia and Alzheimer’s disease psychosis.
The company is headquartered in Redwood City, California, and recently completed a large Series D financing of US $372.5 million to advance its pipeline.
Показать все Скрыть